Bonesupport has developed innovative bioceramic bone graft substitutes, used to treat bone voids. The company’s most advanced products also elute antibiotics, reducing the grave risks of bone infections following complex operations. Bonesupport is now commercializing these innovations internationally, rapidly building its sales capacity and revenues. In parallel, large and important clinical studies are expanding the impressive evidence of efficacy, safety and cost effectiveness.
Industrifonden invested in Bonesupport as part of a strong syndicate, putting in the place the funding and long term thinking necessary to bring medical technology successfully to the market. Bonesupport was listed on Stockholm Nasdaq in 2017, widening the ownership further and setting a strong foundation for long term growth.